close

Enter

Log in using OpenID

Hemophehilia Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026

embed
The global hemophehilia treatment market is forecasted to value over US$ 15 billion by the end of 2026 and grow at a CAGR of over 5% during the forecast period of 2019-2026. Hemophilia is a hereditary genetic disorder where the body’s coagulation co
Hemophehilia Treatment Market Global Trends, Market Share, Industry Size, Growth,
Opportunities, and Market Forecast 2019 to 2026
The global hemophehilia treatment market is forecasted to value over US$ 15 billion by
the end of 2026 and grow at a CAGR of over 5% during the forecast period of 2019-2026.
Hemophilia is a hereditary genetic disorder where the body’s coagulation control or blood
clotting ability is impaired. Basically, due to lack of sufficient amount of blood-clotting proteins
or clotting factors, your blood is unable to clot normally. The inherited hemophilia is generally
found in men as it is passed to them by the X chromosome of their mother. Hemophilia occurs
in three forms – hemophilia A, hemophilia B and hemophilia C. The most commonly formed is
the hemophilia A which is due to lack of factor VIII. Hemophilia B occurs due to lack of factor IX
and hemophilia C occurs due to lack of factor XI. Utilization of innovative techniques and
technological advancements are the driving force for the growth of the global market.
According to World Federation of Hemophilia (WFH), hemophilia A affects 1 in 5000 males
that take birth. It is estimated that around 75% of the global hemophilia patient pool has no
proper access to treatment. Therefore, in order to provide consistent treatment for patients,
agencies like Hemophilia Association of America (HAA) have pursued key market players for
the introduction of co-pay assistance initiatives. For instance, CSL Behring made a donation of
1.5 million units of their anti-hemophilic agents on world hemophilia day which is on April 17.
At present, there is no cure present for hemophilia A and treatments are primarily conducted
to manage the disease. Due to the lack of provision of medical needs and monopolistic
opportunities for manufacturers, there is a huge demand for effective hemophilia management.
Also, due to the presence of limited amount of therapies and regulatory authorities facing a
huge task on the treatment of these disorders, the research and development also get a boost
so that they can identify curative agents which in turn will help to accelerate growth during the
forecast period.
Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=196&page=requestsample
Insights on Hemophilia Treatment Market:
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the world
North America is expected to be a major shareholder of the global market due to high
awareness and supportive regulatory policies. European region follows North America and is
expected to have a significant share during the forecast period. Asia Pacific regions are
expected to experience a rapid market growth rate due to changing healthcare policies and
increasing awareness. Latin America and the rest of the world are both expected to possess a
small fraction of the global market due to lack of awareness.
By Type of Product
• Recombinant clotting factors concentrate
• Plasma derived factor concentrates
By Type of Disease
• Hemophilia A
• Hemophilia B
• Hemophilia C
Hemophilia A treatments are expected to grow at a higher rate in the market as compared to
hemophilia B and hemophilia C during the forecast period due to the prevalence of the disease
throughout the world.
Purchase a Copy of this Premium Research Report & Ask for Discount:
https://www.futurewiseresearch.com/requestsample.aspx?id=196&page=askfordiscount
By End User
• Hospital
• Clinic
• Others
The hospital segment is expected to get a boost in the market growth during the forecast
period as more and more multi-speciality hospitals are being built which provide hemophilia
treatments and has an infrastructural advantage over the clinics and this trend will be
observed in the North American and European regions due to the high spending capacity of the
general population. On the other hand, clinic treatments will obtain a rapid growth rate in
emerging economies due to lesser treatment cost as compared to hospitals.
Competitive Landscape:
• Baxter International Inc.
• Bayer AG
• Pfizer
• Biogen Idec Inc.
Baxter International Inc. has obtained approval for Obizur, which is a recombinant concentrate
for treating hemophilia A which will help them get some market share during the forecast
period because it is the first recombinant porcine FVIII treatment for acquired hemophilia A.
Bayer has got their injection named Jivi FDA-approved last year for treatment for patients aged
12 or above which will help replace reduced or missing factor VIII and this too will help them
acquire a good growth rate during the forecast period. Pfizer has initiated a phase-3 study for
safety evaluation of current therapy of factor IX prophylaxis replacement therapy which will
help them gain some traction in the market during the forecast period.
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global hemophilia treatment market by
region, by type of product, by type of disease, by end user, by market players
• To cater comprehensive information on factors impacting market growth (drivers,
restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe,
Asia Pacific, Latin America
• To record evaluate and competitive landscape mapping- product launches, technological
advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core
competencies
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised
solutions for our clients. Through in-depth market insights and consultancy, we present our
clients with the tools they need to be at the forefront of their industry – a position secured for
far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
Author
Merin John
Merin John263   documents Email
1/--pages
Report inappropriate content